Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think there is a little FUD in that article and while they said MO was seen to decrease cholesterol and triglycerides they claim the data indictees MO may cause inflammation. So now the Chief Fudster will write articles that chronic use of MO causes inflammation and the reason why Reduce it was successful. Give him a couple of weeks and let’s see if the FUD flies.
Now would be a great time to convince one or more big pharmaceuticals to buy a small percentage of the company on the open market. Once that happens Amarin should work to leverage the equity partners sales and marketing experience. Best test run for a big pharmaceutical and only all upside. If they want to buy Amarin out they lowered the acquisition cost through the equity stake. If they don’t, they participate in share appreciation through growth or a buyout from another big player. This is a perfect time for KM to build up relationships and push the manipulators out of the stock. Just a 5 to 10% stake will do.
Seems weird and no mention of dosage, frequency or anything else. I think the Vascepa colon cancer trial wraps up in November so maybe we see something positive out of that.
What happened to the trial? Is it ongoing or did they ever start? Sounds like something that might infringe on the EU patents.
Sorry if this was already posted, looks like we made a list on Robinhood:
https://pennystocks.com/featured/2021/08/12/top-penny-stocks-robinhood-buy-3-names-now/?amp
Generic lovazza is what is eating into our growth and I am sad to say that two family members in NY were told by their cardiologists that V is a trig drug. One family member was told their trigs were fine so they left without a script. The other was given a script for GL and he claims it’s too hard on his stomach and stopped taking it altogether. I think these scripts are getting swapped for GL and I think GL has lots of script attrition because it’s on on your stomach. I blame the Amarin sales and marketing team. I gave my relatives the information to hand to their cardiologist for a real V script. They will let me know what happens on their next appointment.
I said it before the best way to screw wall street is to partner with one or more large pharmaceutical that includes the requirement they buy 5 to 10% of the company on the open market. Could you imagine AZN holds 10% and works with Amarin on combo therapies while helping with their EU rollout. Pfizer buys 10% and works on combo therapies, COVID and supplements the US Amarin sales reps with their own. They can pay Pfizer a commission for sales. At the end each can buyout the parts of Amarin they want.
I really think this is just short positions getting closed out. Going forward the company only has good news….. we know the patent trial will go forward and it will be years before we have an outcome. Germany launches in September, they may sign a partner for some of the other territories soon, we have prepare it in August, I think Mitigate in November and China by the end of the year. I think the colon cancer trial is due in November. All positive catalysts even if the trials fail they would have been considered extra icing on the cake. All we need to really light a match is realize strong US growth in scripts.
Pfizer would be best suited to garner a bigger return paying 25 because of their US sales force. They can influence the doctors to prescribe and push the US volume to a billion with minimal loss to the generics. I don’t think any insurance company nor H and R want to square off against Pfizer. I would gladly take shares instead of cash.
Finally crossed the level of the last time I brought at $5.30 and I stopped buying after that. Seems every time I buy it goes down so I will stay on the sidelines and not jinx it with anymore buys.
Capt you should send some of these to Amarin along with a fee schedule for future scientific and marketing materials. You pull together some brilliant visuals and you should have a freelance arrangement with the company.
We might need to submit a citizens petition to the FDA regarding the required quality and composition of generic drugs that have a label attached to an indication previously approved based on outcome. I can’t see how a generic that is not 100% identical to a brand can be considered equivalent to treat a condition that was proven over years of use using the brand. I can understand a bio marker measurement but not a long term outcome. Amarin has not provided the bio marker that would indicate success over long term use. Nor should they since it protects them against other weasels trying to use that to steal the label.
I asked this same question many months ago and at the very least, if someone knows a reputable lab that does this type of testing I will be happy to call and get a price. I would think we would need to buy multiple random bottles of GV and V to do the testing.
Yes they do and they also need to lose on Amarin, the manipulation is so obvious.
Wow, that is shareholder activism at its finest with good results. I can only hope you guys cash out and throw some of those profits at Amarin. I need this thing to move, papa wants a new 4 series BMW .
Hey LB, were the apes responsible for the run on HOOD?
I’ll tell ya, I don’t get any respect….I once called a sex hotline and got an ear infection.
Yes, that should be the plan after the appeal.
And once again reminds us how Kennedy and JT screwed things up by not filing originally filing in Delaware. I still think the company has a case against Covington.
Now would be a good time for Amarin to talk to Eddingpharm about running a COVID trial in China given the recent lockdowns.
I thought it was close to $400, like $380 but going off of memory. I guess I could have googled it lol.
Stillness, is your point that you believe the wholesale price of Vascepa will be 50% higher than the US? Based on some of your sleuthing. If true that is a game changer.
Has to be angioplasty since it was mentioned they cleared the blockage. I am not aware of any drug or other techniques that can clear the plaque and clots. He should definitely be on Vascepa with stents.
Thanks Capt, I like numbers 1,4 and 8.
Do they have an interim review? If they are scanning at 18 months it would seem they might have some data.
One of my biggest peeves with this company is the lack of global deals that can act as a catalyst and bring in more cash. We have the ROW and little movement in filing for approval or signing a partner. What about central and South America, Australia, Eastern Europe? Plenty of little deals that could add to the market cap. I have harassed Amarin about this for almost 2 years.
I agree, if it’s government they are lazy and accustomed to a work environment that lacks performance metrics and accountability.
My previous Cardiologist left to head up the clinical trials at Duke university and I know he left thinking V helped reverse my CVD disease. Don’t laugh, they assigned me to this doctor at the practice because I am stable. For 4 days a week my doctor works at the FDA as the CMO for cardiac devices. He still believes it is lifestyle habits and not Vascepa. I see him every 4 months and when we are finally face to face I will give him printed material.
I have two stents and they will reach 10 years in September. I credit V for keeping everything clear and my ldl is typically ranges 50 to 57 and my trigs sit between 100 and 109. I have Hopkins affiliated physicians and they recommend under 70 for ldl. I had one artery at 95% and another at 80%.
Anyway I was the one that educated my Cardiologist on V.
Thanks RAF…… the problem is not generics, this is a marketing and image issue as doctors think this is a Trig lowering drug and the reason we see steady GL and rising GV. They have not educated the doctors this is for CVD prevention. Pfizer could double sales in 30 days.
Hey BB, good to see you are still around. When do the apes start to go bananas for Amarin and fling some of their feces at the stock manipulators.
We need to help Amarin get the word out on V, they retweeted and commented on the below post. Please retweet and comment with a link to the Vascepa website.
#Cardiovascualrdisease in women is understudied, underdiagnosed, undertreated and women are under-represented in clinical trials. It’s time we #RethinkCVRisk in women. https://t.co/wKHLCvsoDF
— Amarin (@Amarincorp) July 16, 2021
We could try one last fundraiser to acquire several bottles of each to test content and oxidation. We need to find a lab that will give us a quote. If we say testing 4 bottles each that’s about 3k for the drugs plus lab fees and reports.
Just disgusting that people can’t wear clothes when trading stocks .
Thanks Lizzy and it looks like someone is again trying to stockpile a bunch of shares for another arranged sale. Hopefully our last buying opportunity.
North4000 or another board attorney might be able to chime in. I think the difference is Amarin with the new formulation will have a composition of matter patent and I believe the patents that were challenged for Marine were methods of use. Composition of matter is not easily challenged as obvious.
You might even say the article was a soft bash piece, after reading it you come away saying why buy it.
I thought that article was a bit of a circle jerk and he missed a few points:
In the US Amarin has market erosion due to the skinny label and not a lost market. They still have CVD patents.
Europe is protected for 10 years and the patent fight, if any would deal with the CVD indication and not the trig indication. He totally missed that which has not been litigated in the US.
Amarin is not selling V in China, a Chinese company is the direct marketing partner. It’s a different dynamic and when they want to steal the IP they will go about it by asking Amarin to use a Chinese API provider to supply the Chinese marketer. They play the long game and as soon as Amarin’s patents run out in the US and EU they will swoop in and be happy to provide all the generics with supply.
The article failed to mention other indications
Is that picture of Janet before or after she had lunch with Biobillionaire….. .
I thought FFS said they bottom was $3.56….I have my buy order in at $3.61.